-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
InMed Pharmaceuticals Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q4 2020 to Q3 2023.
- InMed Pharmaceuticals Inc. Operating Income (Loss) for the quarter ending September 30, 2023 was -$2.54M, a 27.7% increase year-over-year.
- InMed Pharmaceuticals Inc. Operating Income (Loss) for the twelve months ending September 30, 2023 was -$6.97M, a 63.6% increase year-over-year.
- InMed Pharmaceuticals Inc. annual Operating Income (Loss) for 2023 was -$7.95M, a 57.3% increase from 2022.
- InMed Pharmaceuticals Inc. annual Operating Income (Loss) for 2022 was -$18.6M, a 82.3% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)